## AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

 (Currently Amended) A method of inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of formula (i):

wherein:

x and v are each independently 1, 2 or 3;

W is -O-, -N(R<sup>1</sup>)-, -C(R<sup>1</sup>)<sub>2</sub>-, -C(O)-, -OC(O)-, -S(O)<sub>r</sub>-; (where t is 0, 1 or 2),

 $-N(R^1)S(O)_{\Gamma} \text{ (where t is 1 or 2), } -S(O)_2N(R^1)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -OS(O)_2N(R^1)-, -OS$ 

 $-OC(O)N(R^1)-, \ -OC(S)N(R^1)-, \ -N(R^1)C(O)N(R^1)- \ or \ -N(R^1)C(S)N(R^1)-;$ 

 $V \ \text{is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -C(S)O-, -S(O)_{r}} \\ (\text{where t is 1 or 2)},$ 

 $-S(O)_tN(R^1)$ - (where t is 1 or 2) or  $-C(R^{11})H$ ;

each R1 is independently selected from the group consisting of hydrogen,

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2 \ is \ selected from the group consisting of C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl, \\ C_2-C_{12} hydroxyalkyl, \ C_2-C_{12} hydroxyalkyl, C_3-C_{12} cycloalkyl, \\ C_3-C_{12} hydroxyalkyl, C_3-C_{12} cycloalkyl, \\ C_3-C_{12} hydroxyalkyl, C_3-C_{12} cycloalkyl, \\ C_3-C_{12} hydroxyalkyl, \\ C_3-C_{12} cycloalkyl, \\ C_3-C_{12} cyclo$ 

C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl,

C<sub>1</sub>-C<sub>12</sub>heteroaryl, and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^3 \text{ is selected from the group consisting of $C_1\text{-}C_{12}$alkyl, $C_2\text{-}C_{12}$alkeyl, $C_2\text{-}C_{12}$alkeyl, $C_2\text{-}C_{12}$alkeyl, $C_2\text{-}C_{12}$alkeyl, $C_2\text{-}C_{12}$alkeyl, $C_3\text{-}C_{12}$cycloalkyl, $C_3\text{-}C_{12}$cycloalkyl, $R_3\text{-}C_{12}$cycloalkyl, $R_3\text{-}C_{12}$alkeyl, $R_3\text{-$ 

or R3 is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4$ ,  $R^6$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N( $R^{15}$ )<sub>2</sub>;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or Cr-C-alkVI:

or R<sup>7</sup> and R<sup>7a</sup> together, or R<sup>8</sup> and R<sup>8a</sup> together, or R<sup>9</sup> and R<sup>8a</sup> together, or R<sup>4a</sup> and R<sup>5a</sup> together, or R<sup>4a</sup> and R<sup>5a</sup> together are an oxe group, provided that when V-is—C(O)—R<sup>7</sup> and R<sup>7a</sup> together or R<sup>8</sup> and R<sup>8a</sup> together do not form an oxe group, while the remaining R<sup>7</sup> + R<sup>7a</sup> + R<sup>8</sup> + R<sup>8a</sup> + R<sup>9</sup> + R<sup>9a</sup> + R

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^{2}$ , and  $R^{2a}$  together with one of  $R^{8}$ ,  $R^{8a}$ ,  $R^{9}$  and  $R^{9a}$  form an alkylene-bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^{2}$ ,  $R^{7a}$ ,  $R^{8a}$ ,  $R^{9}$ , and  $R^{9a}$  are each independently selected from hydrogen or  $G_{2}$ - $G_{3}$ alkyli;

R11 is hydrogen or C1-C3alkyl; and

each R13 is independently selected from hydrogen or C1-C6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

 (Currently Amended) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):

wherein:

x and y are each independently 1, 2 or 3;

 $\label{eq:wis-o-1} W \text{ is } -O^-, -N(R^1)_-, -C(R^1)_{2^-}, -C(O)_-, -OC(O)_-, -S(O)_\Gamma; \text{ (where t is 0, 1 or 2),} \\ -N(R^1)S(O)_\Gamma \text{ (where t is 1 or 2), } -S(O)_2N(R^1)_-, -C(O)N(R^1)_-, -C(S)N(R^1)_-, -OS(O)_2N(R^1)_-, -OC(O)N(R^1)_-, -OC(S)N(R^1)_-, -N(R^1)C(O)N(R^1)_-, -OC(S)N(R^1)_-, -N(R^1)C(O)N(R^1)_-, -OC(S)N(R^1)_-, -N(R^1)C(O)N(R^1)_-, -OC(S)N(R^1)_-, -N(R^1)C(O)N(R^1)_-, -OC(S)N(R^1)_-, -N(R^1)C(O)N(R^1)_-, -OC(S)N(R^1)_-, -O$ 

 $\label{eq:Vis-C(O)-,-C(S)-,-C(O)N(R^1)-,-C(S)N(R^1)-,-C(O)O-,-C(S)O-,-S(O)-, (where t is 1 or 2), -S(O),N(R^1)- (where t is 1 or 2) or -C(R^1)H;}$ 

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_{1}$ - $C_{12}$ alkyl,  $C_{2}$ - $C_{12}$ hydroxyalkyl,  $C_{4}$ - $C_{12}$ cycloalkylalkyl and  $C_{7}$ - $C_{19}$ aralkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12}\text{alkyl}, C_2\text{-}C_{12}\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_2\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_{43}\text{-}\text{heteroaryl}, \text{and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_{4}\text{-}C_{43}\text{-}\text{heteroaryl}, \text{and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_{4}\text{-}C_{43}\text{-}\text{heteroaryl}, \\ C_{5}\text{-}C_{5}\text{-}\text{heteroaryl}, \\ C_{5}\text{-}C_{5}\text{-}\text{heteroaryl}$ 

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected from the group consisting of $C_1-C_{12}alkyl, $C_2-C_{12}alkenyl, $C_2-C_{12}alkenyl, $C_2-C_{12}alkenyl, $C_2-C_{12}alkenyl, $C_2-C_{12}alkenyl, $C_3-C_{12}alkenyl, $C_3-C_{12}alkeny$ 

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N( $R^{15}$ )<sub>2</sub>;

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},$  and  $R^{10a}$  are each independently selected from

or  $R^7$  and  $R^{7a}$  together, or  $R^9$  and  $R^{8a}$  together, or  $R^9$  and  $R^{8a}$  together, or  $R^{10}$  and  $R^{10a}$  together are an exergeup, provided that when V is -C(O),  $R^7$  and  $R^{7a}$ -together or  $R^8$  and  $R^{8a}$  together do not form an exergeup, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{80}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_2$ alkyl;

or one of  $R^{10}$ ,  $R^{10}$ ,  $R^{10}$ ,  $R^{2}$ , and  $R^{2}$  together with one of  $R^{8}$ ,  $R^{8}$ ,  $R^{9}$  and  $R^{90}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10}$ ,  $R^{7}$ ,  $R^{7}$ ,  $R^{8}$ ,  $R^{9}$ , and  $R^{60}$ -are each independently selected from hydrogen or  $C_{3}$ - $C_{3}$ alkyl;

R<sup>11</sup> is hydrogen or C₁-C₃alkyl; and

each R<sup>13</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

3. (Original) The method of Claim 2 wherein the mammal is a human.

4. (Currently Amended) The method of Claim 3 wherein the disease or condition is selected from the group consisting of Type II diabetes, fatty liver, non-alcoholic steatohepatitis, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, acne, and metabolic syndrome and any combination of these.

- (Original) The method of Claim 4 wherein the disease or condition is Type II
  diabetes.
  - 6. (Original) The method of Claim 4 wherein the disease or condition is obesity.
- (Original) The method of Claim 4 wherein the disease or condition is metabolic syndrome.
  - (Original) The method of Claim 4 wherein the disease or condition is fatty liver.
- (Original) The method of Claim 4 wherein the disease or condition is nonalcoholic steatchepatitis.
  - (Currently Amended) A compound of formula (IIa):

wherein:

x and y are each independently 1, 2 or 3;

 $R^1 \ is \ selected from the group consisting of hydrogen, \ C_1-C_{12} alkyl, \\ C_2-C_{12} hydroxyalkyl, \ C_4-C_{12} cycloalkylalkyl \ and \ C_7-C_{19} aralkyl;$ 

 $R^2 is selected from the group consisting of $C_7-C_{12}alkyl, $C_3-C_{12}alkenyl$, $C_7-C_{12}hydroxyalkyl$, $C_2-C_{12}alkoxyalkyl$, $C_3-C_{12}hydroxyalkenyl$, $C_3-C_{12}cycloalkyl$, $C_4-C_{12}cycloalkylalkyl$, $C_1-C_{12}heteroaryl$, $C_3-C_{12}heterocyclylalkyl$, $C_3-C_{12}heterocyclylalkyl$, $C_3-C_{12}heterocyclyl$, and $C_3-C_{12}heteroarylalkyl$, provided that $R^2$ is not pyrazinyl$, pyridinonyl$, pyrrolidinonyl or imidazolyl$;} \label{eq:reconstant}$ 

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected from the group consisting of $C_3-C_{12}alkyl, $C_3-C_{12}alkenyl, $C_3-C_{12}alkyl, $C_3-C_{12}alkenyl, $C_3-C_{12}alkyl, $C_3-C_{12}cycloalkyl, $C_3-C_{12}cycl$ 

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other,

 $R^4$ ,  $R^5$  and  $R^8$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{15})_2$ ;

 $R^7$ ,  $R^{7a}$ ,  $R^a$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{8a}$ ,  $R^{10}$  and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

er R<sup>o</sup>and R<sup>o</sup>a-together, or R<sup>o</sup>-and R<sup>oa</sup>-together form an exe group, while the remaining R<sup>o</sup>a-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-R<sup>oa</sup>-Roand R<sup>oa</sup>-are each independently selected from hydrogen or Ca-Callytin

er one of  $R^2$ ,  $R^{2a}$ ,  $R^{10}$  and  $R^{10a}$ , together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{20}$ , form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^7$ ,  $R^8$ ,  $R^8$ ,  $R^9$  and  $R^{6a}$  are each independently selected from hydrogen or  $C_3$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1\text{-}C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

. 11. (Currently Amended) The compound of Claim 10 wherein:

x and y are each independently 1, 2-er-3;

R<sup>1</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl,

C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>18</sub>aralkyl;

 $R^2$  is selected from the group consisting of  $C_7$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ alkenyl,  $C_3$ - $C_{12}$ hydroxyalkyl,  $C_3$ - $C_{12}$ hlydroxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_3$ - $C_{12}$ cycloalkylalkyl,  $C_3$ - $C_{12}$ cycloalkylalkyl,  $C_3$ - $C_{12}$ -aralkyl,  $C_1$ - $C_{12}$ -heteroaryl,  $C_3$ - $C_{12}$ -heterocyclylalkyl,  $C_3$ - $C_{12}$ -heterocyclyl and  $C_3$ - $C_{12}$ -heteroarylalkyl, provided that  $R^2$  is not pyrazinyl, pyridinonyl, pyrrolldinonyl or imidazolyl;

 $R^3 \text{ is selected from the group consisting of $C_3-C_{12}alkyl, $C_3-C_{12}alkenyl,$$$ $C_5-C_{12}hydroxyalkyl, $C_3-C_{12}hydroxyalkyl, $C_3-C_{12}alkoxyalkyl, $C_3-C_{12}cycloalkyl,$$$$ $C_4-C_{12}cycloalkyl, aryl, $C_7-C_{12}aralkyl, $C_3-C_{12}heterocyclyl, $C_3-C_{12}heterocyclylalkyl, $C_1-C_{12}heteroaryl and $C_3-C_{12}heteroarylalkyl;$$$$$ 

 $R^4$ ,  $R^5$  and  $R^5$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N( $R^{15}$ )<sub>2</sub>;

 $R^7,\,R^{7a},\,R^a,\,R^{a_0},\,R^a,\,R^{9a},\,R^{10}$  and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1\text{-}C_6$ alkyl.

(Original) The compound of Claim 11 wherein:

x and y are each 1;

R1 is selected from the group consisting of hydrogen or C1-C12alkyl;

R2 is selected from the group consisting of C7-C12alkyl, C3-C12alkenyl,

 $C_{3}-C_{12} \\ \text{cycloalkyl}, \ C_{4}-C_{12} \\ \text{cycloalkylalkyl}, \ C_{13}-C_{19} \\ \text{aralkyl}, \ C_{1}-C_{12} \\ \text{heteroaryl}, \ C_{3}-C_{12} \\ \text{heteroarylalkyl}; \\ \text{and} \ C_{3}-C_{12} \\ \text{heteroarylalkyl}; \\ \text{hetero$ 

 $R^3 is selected from the group consisting of C_3-C_{12} alkyl, C_3-C_{12} cycloalkyl, \\ C_4-C_{12} cycloalkylalkyl, aryl, C_7-C_{12} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_1-C_{12} heteroaryl and C_3-C_{12} heteroarylalkyl; \\$ 

 $R^4$ ,  $R^5$  and  $R^8$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N( $R^{18}$ )<sub>2</sub>;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$  and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each R<sup>13</sup> is independently selected from hydrogen or C₁-C₀alkyl.

(Original) The compound of Claim 12 wherein:
 R<sup>2</sup> is C<sub>3</sub>-C<sub>12</sub>cycloalkyl or C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl;
 R<sup>3</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>12</sub>cycloalkyl or

## C4-C12cycloalkylalkyl;

 $R^4$ ,  $R^5$  and  $R^6$  are each hydrogen; and  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$   $R^{10}$  and  $R^{10a}$  are each hydrogen or  $C_1$ - $C_3$ alkyl.

14. (Original) The compound of Claim 13 wherein:

R2 is C2-C12cvcloalkyl; and

R3 is C3-C12cycloalkyl.

- (Original) The compound of Claim 14, namely, Cyclohexanecarboxylic acid [6-(4-cyclohexanecarbonyl-piperazin-1-yl)pyridin-3-yl]amide.
- 16. (Original) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 10.
- (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.
  - 18. (Currently Amended) A compound of formula (IIb):

$$R^{1} = R^{4} = R^{6} R^{10a} R^{7a} R^{7a}$$

$$R^{2} = R^{6} R^{9a} R^{8a} R^{8a}$$

$$R^{2} = R^{8a} R^{8a}$$
(IIIb)

wherein:

x and y are each independently 1, 2 or 3;

 $R^1 \ is \ selected from the group consisting of hydrogen, \ C_{1^2}C_{12} alkyl, \\ C_{2^-}C_{12} hydroxyalkyl, \ C_{4^-}C_{12} cycloalkylalkyl \ and \ C_{7^-}C_{19} aralkyl;$ 

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12}\text{alkyl}, C_2\text{-}C_{12}\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_1\text{-}C_6\text{alkoxy}, C_3\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{ heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ \text{-}C_{12}\text{-}C_$ 

C.-C.-heteroarvl and C.-C.-heteroarvlalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other,

 $R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{trihaloalky},\ C_1\text{-}C_0\text{ellkyl},\ C_1\text{-}C_0\text{e$ 

 $R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{15})_z$ ;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{9a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^9$  and  $R^{9a}$ -together, or  $R^{10}$  and  $R^{10a}$ -together form an exe group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{9a}$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_2$ alkyl;

or one of  $R^7$ ,  $R^{7o}$ ,  $R^{1o}$  and  $R^{1oo}$ , together with one of  $R^8$ ,  $R^{8o}$ ,  $R^9$  and  $R^{1o}$ , form an alkylene bridge, while the remaining  $R^{1o}$ ,  $R^{1o}$ ,  $R^{7o}$ ,  $R^7$ ,  $R^8$ ,  $R^8$ ,  $R^9$ , and  $R^{1o}$  are each independently selected from hydrogen or  $G_4$ - $G_5$ alkyl; and

each  $R^{12}$  is independently selected from hydrogen,  $C_{1^{\circ}}C_{0}$ alkyl,  $C_{0}$ - $C_{0}$ cycloalkyl, aryl or aralkyl; and

each R¹³ is independently selected from hydrogen or C₁-C₅alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable sait thereof, a pharmaceutical composition thereof or a prodrug thereof.

(Currently Amended) The compound of Claim 18 wherein:
 x and y are each independently 1, 2-or-3;
 R¹ is selected from the group consisting of hydrogen, C₁-C₁₂alkyl,

C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylaikyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>16</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>7</sub>-C<sub>16</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

 $R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1\text{-}C_0\text{ellkyl}$ ,  $C_1\text{-}C_0\text{trihaloalky}$ ,  $C_1\text{-}C_0\text{ellkyl}$ ,  $C_1\text{-}C_0\text{ellkyl}$ ,  $C_1\text{-}C_0\text{ellkyl}$ ,  $C_1\text{-}C_0\text{ellkyl}$ ,  $C_1\text{-}C_0\text{ellkyl}$ ,  $C_1\text{-}C_0\text{ellkyl}$ , heterocyclyl, heteroaryl and heteroarylcycloalkyl, provided that  $R^3$  is not phenyl substituted with optionally substituted thienyl;

 $R^4$ ,  $R^5$  and  $R^5$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{15})_2$ ;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or Cr-Callkyl. or

 $R^{10}$  and  $R^{10a}$  together form an oxo group and the remaining  $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9$  and  $R^{9a}$  are each hydrogen;

 $each\ R^{12}\ is\ independently\ selected\ from\ hydrogen,\ C_1\text{-}C_6alkyl,\ C_3\text{-}C_ccycloalkyl,}$  aryl or aralkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1\text{--}C_6alkyl.$ 

(Original) The compound of Claim 19 wherein:

x and y are each 1;

R1 is hydrogen or C1-C12alkyl;

 $R^2 is selected from the group consisting of $C_1-C_{12}$alkyl, $C_2-C_{12}$alkenyl, $C_2-C_{12}$hydroxyalkyl, $C_2-C_{12}$hydroxyalkyl, $C_3-C_{12}$hydroxyalkyl, $C_3-C_{12}$alkoxy, $C_3-C_{12}$alkoxyalkyl, $C_3-C_{12}$cycloalkyl, $C_3-C_{12}$heterocyclyl, $C_3-C_{12}$heterocyclylalkyl, $C_3-C_{12}$heteroaryl and $C_3-C_{12}$heteroarylalkyl; $C_3-C_{12}$heteroaryl and $C_3-C_{12}$heteroarylalkyl; $C_3-C_{12}$heteroa$ 

 $R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1\text{-}C_0\text{elkyl},\ C_1\text{-}C_0\text{trihaloalkyy},\ C_1\text{-}C_0\text{elkyl},\ C_1\text{-}C_0\text{e$ 

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each hydrogen;

R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen; or

 $R^{10}$  and  $R^{10a}$  together form an oxo group and the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  are each hydrogen; and

each  $R^{12}$  is independently selected from hydrogen,  $C_t$ - $C_e$ alkyl,  $C_3$ - $C_e$ cycloalkyl, arvl or aralkyl.

21. (Original) The compound of Claim 20 wherein:

R2 is C1-C12alkyl; and

 $R^3$  is phenyl optionally substituted by one or more substituents selected from halo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy.

 (Original) The compound of Claim 21 selected from the group consisting of the following:

4-Methylpentanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;
Hexanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;
Heptanoic acid {6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide;
Heptanoic acid {6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl]amide; and
Hexanoic acid {6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl]amide.

23. (Original) The compound of Claim 20 wherein:

R2 is C3-C12cycloalkyl; and

 $R^3$  is phenyl optionally substituted by one or more substituents selected from halo,  $C_1$ - $C_6$ trihaloalkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy.

- 24. (Original) The compound of Claim 23, namely, Cyclohexanecarboxylic acid {6-{4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}amide.
  - 25. (Original) The compound of Claim 20 wherein:

 $R^2 \text{ is } C_{7^*}C_{12} \text{aralkyl optionally substituted by one or more substituents selected from halo, } C_{1^*}C_8 \text{alkyl, } C_{1^*}C_8 \text{trihaloalkyl and } C_{1^*}C_8 \text{trihaloalkoxy; and}$ 

 $R^3 \ \text{is phenyl optionally substituted by one or more substituents selected from halo, $C_1\text{-}C_6$ alkyl, $C_1\text{-}C_6$ trihaloalkyl and $C_1\text{-}C_6$ trihaloalkoxy.}$ 

 (Original) The compound of Claim 25 selected from the group consisting of the following:

3-Phenyl-N-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}propionamide;

4-Phenyl-N-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}butyramide; and

N-{6-[2-Oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}-4-phenylbutyramide.

(Original) A method of treating a disease or condition mediated by stearoyl-CoA
desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in
need thereof a therapeutically effective amount of a compound of Claim 18.

- (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 18.
  - 29. (Currently Amended) The compound of formula (III):

$$R^{2} = \sum_{N=1}^{R^{4}} \sum_{N=1}^{R^{4}} \sum_{N=1}^{R^{5}} \sum_{N=1}^{R^{10a}} \sum_{N=1}^{R^{10}} \sum_{N=1}^{R^{7}a} \sum_{N=1}^{R^{3}} \sum_{N=1}^{R^{10}} \sum_{N=1}^{R^{10}}$$

wherein:

x and v are each independently 1, 2 or 3;

 $V_a \text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -C(O)O-, -C(S)O-, -S(O),-(where t is 1 or 2) or -S(O),N(R^1)- (where t is 1 or 2);} \\$ 

each R1 is independently selected from the group consisting of hydrogen,

C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;

 $R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_1$ - $C_6$ alkoxy,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_3$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected from the group consisting of $C_1\text{-}C_{12}$alkyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_3\text{-}C_{12}$alkenyl, $C_3\text$ 

Docket No.: 17243/003001

Application No.: 10/566,193

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4$ ,  $R^5$  and  $R^5$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N( $R^{15}$ )<sub>2</sub>;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or R<sup>7</sup> and R<sup>7a</sup>-together, or R<sup>8</sup> and R<sup>8a</sup>-together, or R<sup>9</sup> and R<sup>8a</sup>-together, or R<sup>4a</sup>-and R<sup>4a</sup>-together are an exe group, provided that when V<sub>a</sub>-is - C(O), R<sup>7</sup> and R<sup>7a</sup>-together or R<sup>8</sup> and R<sup>8a</sup>-together de not form an exe group, while the remaining R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>8a</sup>, R<sup>1a</sup>, and R<sup>1aa</sup>-are each independently selected from hydrogen or C<sub>4</sub>-C<sub>3</sub>alkyl;

or-one of  $R^{10}$ ,  $R^{10}$ ,  $R^{7}$ , and  $R^{7}$ , together with one of  $R^{8}$ ,  $R^{8}$ ,  $R^{9}$ , and  $R^{9}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10}$ ,  $R^{7}$ ,  $R^{7}$ ,  $R^{8}$ ,  $R^{8}$ ,  $R^{9}$ , and  $R^{98}$  are each independently selected from hydrogen or  $C_{2}$ - $C_{3}$ alkyl; and

each R<sup>13</sup> is independently selected from hydrogen or C₁-C₀alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

(Currently Amended) The compound of Claim 29 wherein:
 x and y are each independently 1, 2-er-3;
 V<sub>a</sub> is -C(O)- or -C(S)-;

R<sup>1</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl,

 $C_2\text{--}C_{12}\text{hydroxyalkyl},\ C_4\text{--}C_{12}\text{cycloalkylalkyl}\ \text{and}\ C_7\text{--}C_{19}\text{aralkyl};$ 

 $R^2 \text{ is selected from the group consisting of } C_1\text{--}C_{12}\text{alkyl}, C_2\text{--}C_{12}\text{alkenyl}, \\ C_2\text{--}C_{12}\text{hydroxyalkyl}, C_2\text{--}C_{12}\text{hydroxyalkenyl}, C_1\text{--}C_6\text{alkoxy}, C_3\text{--}C_{12}\text{alkoxyalkyl}, C_3\text{--}C_{12}\text{cycloalkyl}, \\ C_4\text{--}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{--}C_1\text{aralkyl}, C_3\text{--}C_{12}\text{ heterocyclyl}, C_3\text{--}C_{12}\text{heterocyclylalkyl}, \\ C_7\text{--}C_1\text{heteroaryl} \text{ and } C_3\text{--}C_1\text{heteroarylalkyl}; \\ C_7\text{--}C_1\text{heteroaryl} \text{ and } C_3\text{--}C_1\text{heteroarylalkyl}; \\ C_7\text{--}C_1\text{heteroaryl} \text{ and } C_3\text{--}C_1\text{--}\text{heteroarylalkyl}; \\ C_7\text{--}C_1\text{heteroaryl} \text{ and } C_3\text{--}C_1\text{--}\text{heteroarylalkyl}; \\ C_7\text{--}C_1\text{--}\text{heteroaryl} \text{ and } C_3\text{--}C_1\text{--}\text{heteroarylalkyl}; \\ C_7\text{--}C_1\text{--}\text{heteroarylalkyl}; \\ C_$ 

 $R^3 \text{ is selected from the group consisting of } C_{1^*}C_{12}\text{alkyl}, C_{2^*}C_{12}\text{alkenyl}, \\ C_{2^*}C_{12}\text{hydroxyalkyl}, C_{2^*}C_{12}\text{hydroxyalkenyl}, C_{2^*}C_{12}\text{alkoxyalkyl}, C_{3^*}C_{12}\text{cycloalkyl}, \\ C_{4^*}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_{7^*}C_{19}\text{aralkyl}, C_{3^*}C_{12}\text{heterocyclyl}, C_{3^*}C_{12}\text{heterocyclylalkyl}, \\ C_{1^*}C_{1^*}\text{beteroaryl} \text{ and } C_{3^*}C_{12}\text{heteroarylalkyl}; \\$ 

 $R^4$ ,  $R^5$  and  $R^8$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N( $R^{18}$ )<sub>2</sub>;

 $R^7, R^{7a}, R^8, R^{8a}, R^9, R^{8a}, R^{10}, \text{ and } R^{10a} \text{ are each independently selected from hydrogen or } C_1\text{-} C_3\text{alkyl}; \text{ and }$ 

each  $R^{13}$  is independently selected from hydrogen or  $C_1\text{-}C_\epsilon alkyl$ .

31. (Original) The compound of Claim 30 wherein:

x and y are each 1;

V<sub>a</sub> is -C(O)-;

R1 is hydrogen or C1-C12alkyl;

 $R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, \\ C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_1-C_6alkoxy, C_3-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, \\ C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12}heterocyclylalkyl, \\ C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl; \\$ 

 $R^3$  is naphthyl or phenyl, each optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl,  $C_1$ - $C_6$ trihaloalkoxy,  $C_1$ - $C_6$ alkylsulfonyl, -N( $R^{12}$ )<sub>2</sub>, -OC(O) $R^{12}$ , -C(O)O $R^{12}$ , -S(O)<sub>2</sub>N( $R^{12}$ )<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl;

R4, R5 and R6 are each hydrogen;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each hydrogen; and each  $R^{12}$  is independently selected from hydrogen,  $C_1$ - $C_0$ alkyl,  $C_3$ - $C_0$ cycloalkyl, aryl or aralkyl.

32. (Original) The compound of Claim 31 wherein:

 $R^2 \text{ is } C_1\text{-}C_{12}\text{alkyl or } C_7\text{-}C_{12}\text{aralkyl optionally substituted by one or more substituents selected from the group consisting of halo, $C_1\text{-}C_6\text{alkyl}$, $C_1\text{-}C_6\text{trihaloalkyl}$ and $C_1\text{-}C_6\text{trihaloalkoxy}$;}$ 

 $R^3 \ \text{is naphthyl or phenyl, each optionally substituted by one or more substituents} \\ \text{selected from the group consisting of halo, $C_1-C_2 = C_2 = C$ 

33. (Original) The compound of Claim 32 selected from the group consisting of the following:

Pentane-1-sulfonic acid (6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Butane-1-sulfonic acid (6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl]amide; Hexane-1-sulfonic acid (6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl]amide;

Docket No.: 17243/003001

Pentane-1-sulfonic acid {6-[4-(2-bromobenzoyl)piperazin-1-yl]pyridin-3-yl]amide;

Hexane-1-sulfonic acid {6-[4-(2,5-dichlorobenzoyl)-piperazin-1-yl]pyridin-3-yl]amide;

Pentane-1-sulfonic acid {6-[4-(2,5-dichlorobenzoyl)-piperazin-1-yl]pyridin-3-yl]amide;

Hexane-1-sulfonic acid {6-[4-(naphthalene-1-carbonyl)-piperazin-1-yl]pyridin-3-yl]amide;

Pentane-1-sulfonic acid {6-[4-(naphthalene-1-carbonyl)-piperazin-1-yl]pyridin-3-yl]amide; and

3-Phenylpropane-1-sulfonic acid {6-[4-(2-trifluoromethyl-benzoyl)piperazin-1-yl]pyridin-3-yl]amide.

34. (Original) The compound of Claim 31 wherein:  $R^2 \text{ is } C_{4^*}C_{12} \text{cycloalkylalkyl, } C_{7^*}C_{19} \text{aralkyl, } C_{3^*}C_{12} \text{heterocyclylalkyl or } C_{3^*}C_{12} \text{heteroarylalkyl'};$ 

 $R^3 \ \text{is naphthyl or phenyl, each optionally substituted by one or more substituents} \\ \text{selected from the group consisting of halo, $C_1-C_0\text{elkyl}$, $C_1-C_0\text{trihaloalkyl}$ and $C_1-C_0\text{trihaloalkoxy}$.}$ 

- 35. (Original) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 29.
- (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 29.
  - 37. (Currently Amended) The compound of formula (IV):

wherein:

x and y are each independently 1<del>, 2 or 3</del>;

 $V_a$  is -C(O)-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -C(S)N(R<sup>1</sup>)-, -C(O)O-, -C(S)O-, -S(O)<sub>t</sub>-(where t

is 1 or 2) or -S(O)<sub>t</sub>N(R1)- (where t is 1 or 2);

 $each \ R^1 \ is \ independently \ selected \ from \ the \ group \ consisting \ of \ hydrogen, \\ C_{1^-}C_{12} likyl, \ C_{2^-}C_{12} hydroxyalkyl, \ C_{4^-}C_{12} cycloalkylalkyl \ and \ C_{7^-}C_{16} a ralkyl;$ 

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12} \text{alkyl}, C_2\text{-}C_{12} \text{alkenyl}, C_2\text{-}C_{12} \text{hydroxyalkyl}, C_3\text{-}C_{12} \text{nydroxyalkenyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, \\ C_4\text{-}C_{12} \text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19} \text{aralkyl}, C_3\text{-}C_{12} \text{ heterocyclyl}, C_3\text{-}C_{12} \text{heterocyclylalkyl}, \\ C_1\text{-}C_{12} \text{heteroaryl} \text{ and } C_3\text{-}C_{12} \text{heteroarylalkyl}; \\ \end{aligned}$ 

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^3 \ is \ selected from the group consisting of $C_1\text{-}C_{12}$alkyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$bydroxyalkyl, $C_2\text{-}C_{12}$bydroxyalkyl, $C_3\text{-}C_{12}$alkenyl, $C_3\text{-}C_{12}$alkenyl, $C_3\text{-}C_{12}$bydroxyalkyl, $C_3\text{-}C_{12}$beterocyclyl, $C_3\text{-}C_{12}$beterocyclylalkyl, $C_3\text{-}C_1$beterocyclylalkyl, $C_3\text{-}C_1$beterocycl$ 

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or Cr-Csalkyl;

or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together, or  $R^9$  and  $R^{8a}$  together, or  $R^{10}$  and  $R^{4a}$  together are an exe-group, provided that when  $V_a$  is C(O),  $R^7$  and  $R^{7a}$  together or  $R^8$  and  $R^{8a}$  together do not form an exe-group, while the remaining  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{8a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_4$ - $C_4$ - $C_4$ - $C_4$ - $C_5$ -

or-one of R<sup>10</sup>-R<sup>10</sup>-R<sup>2</sup>-and R<sup>20</sup>-together with one of R<sup>8</sup>-R<sup>80</sup>-R<sup>2</sup>-and R<sup>80</sup>-form an alkylene-bridge, while the remaining R<sup>10</sup>-R<sup>100</sup>-R<sup>20</sup>-R<sup>2</sup>-R<sup>2</sup>-R<sup>8</sup>-R<sup>8</sup>-R<sup>9</sup>, and R<sup>80</sup>-are each independently-selected from hydrogen-or C<sub>3</sub>-C<sub>3</sub>alkyl; and

each R13 is independently selected from hydrogen or C1-C6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

38. (Currently Amended) The compound of Claim 37 wherein:

x and v are each independently 1, 2 or 3;

 $V_s$  is -C(O)-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -C(S)N(R<sup>1</sup>)-, -C(O)O-, -S(O)<sub>C</sub>(where t is 1 or 2) or -S(O)N(R<sup>1</sup>)- (where t is 1 or 2);

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

 $R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_3$ - $C_{12}$ cycloalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_1$ -heteroaryl and  $C_3$ - $C_1$ -heteroarylalkyl;

 $R^3 \ is \ selected \ from \ the \ group \ consisting \ of \ C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl, \\ C_2-C_{12} hydroxyalkyl, \ C_2-C_{12} hydroxyalkenyl, \ C_2-C_{12} alkoxyalkyl, \ C_3-C_{12} cycloalkyl, \\ C_4-C_{12} cycloalkylalkyl, \ aryl, \ C_7-C_{19} aralkyl, \ C_3-C_{12} heterocyclylalkyl, \\ C_1-C_{12} heteroaryl \ and \ C_3-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroaryl \ and \ C_3-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroaryl \ and \ C_3-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroarylalkyl, \ C_1-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroarylalkyl, \ C_1-C_{12} heteroarylalkyl; \\ C_1-C_{12} heteroarylalkyl, \ C_$ 

 $R^4$ ,  $R^5$  and  $R^8$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},\,and\,R^{10a}\,are\,each\,independently\,selected\,from\,hydrogen\,or\,C_1-C_5alkyl;\,and$ 

each R<sup>13</sup> is independently selected from hydrogen or C₁-C<sub>8</sub>alkyl.

39. (Original) The compound of Claim 38 wherein:

x and y are each 1;

V<sub>a</sub> is -C(O)-:

each R1 is independently hydrogen or C1-C6alkyl;

 $R^2 \text{ is selected from the group consisting of $C_1\text{-}C_{12}\text{alkeyl}$, $C_2\text{-}C_{12}\text{alkenyl}$, $C_3\text{-}C_{12}\text{hydroxyalkyl}$, $C_3\text{-}C_{12}\text{hydroxyalkenyl}$, $C_3\text{-}C_{12}\text{alkoxyalkyl}$, $C_3\text{-}C_{12}\text{cycloalkyl}$, $C_4\text{-}C_{12}\text{cycloalkyl}$, aryl, $C_7\text{-}C_{19}\text{aralkyl}$, $C_3\text{-}C_{12}$ heterocyclyl, $C_3\text{-}C_{12}\text{heterocyclylalkyl}$, $C_1\text{-}C_1\text{-}heteroaryl and $C_3\text{-}C_1\text{-}heteroarylalkyl}$, $C_1\text{-}C_1\text{-}heteroarylalkyl}$, $C_1\text{-}C_1\text{-}heteroary$ 

 $R^3 \text{ is selected from the group consisting of } C_3\text{-}C_{12} \text{alkyl}, C_3\text{-}C_{12} \text{alkenyl}, \\ C_3\text{-}C_{12} \text{hydroxyalkyl}, C_3\text{-}C_{12} \text{hydroxyalkenyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, \\ C_4\text{-}C_{12} \text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_1 \text{aralkyl}, C_3\text{-}C_{12} \text{heterocyclyl}, C_3\text{-}C_1 \text{heterocyclylalkyl}, \\ \text{cycloalkylalkyl}, C_7\text{-}C_1 \text{aralkyl}, C_7\text{-}C_1 \text{heterocyclylalkyl}, \\ \text{cycloalkylalkyl}, C_7\text{-}C_1 \text{-}C_1 \text{-}C_1$ 

R4, R5 and R6 are each hydrogen;

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},$  and  $R^{10a}$  are each hydrogen; and

each  $R^{12}$  is independently selected from hydrogen,  $C_t$ - $C_e$ alkyl,  $C_5$ - $C_e$ cycloalkyl, aryl or aralkyl.

40. (Original) The compound of Claim 39 wherein:

R<sup>2</sup> is C<sub>1</sub>-C<sub>12</sub>alkyl or C<sub>7</sub>-C<sub>12</sub>aralkyl optionally substituted by one or more substituents selected from the group consisting of halo, C₁-C₀alkyl, C₁-C₀trihaloalkyl and C₁-C₀trihaloalkoxy; and

 $R^{s} \ is \ selected from the group consisting of C_{5}\text{-}C_{12} \text{cycloalkyl, aryl,}$   $C_{5}\text{-}C_{12} \text{heterocyclyl or } C_{1}\text{-}C_{12} \ \text{heteroaryl.}$ 

- 41. (Original) The compound of Claim 40 wherein R3 is C3-C12cycloalkyl.
- 42. (Original) The compound of Claim 41 selected from the group consisting of the following:
- 1-[6-(4-Cyclohexanecarbonylpiperazin-1-yl)pyridin-3-yl]-3-pentylurea; and 1-[6-(4-Cyclopentanecarbonylpiperazin-1-yl)pyridin-3-yl]-3-pentylurea.
- 43. (Original) The compound of Claim 40 wherein  $R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy.
- 44. (Original) The compound of Claim 43 selected from the group consisting of the following:
- 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea;
- 1-Butyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea;
- 1-Phenethyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl}urea;
- 1-Benzyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; and
- 1-(4-Fluorobenzyl)-3-{6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridin-3-yl}urea.
- 45. (Original) The compound of Claim 40 wherein R³ is piperidinyl optionally substituted by C<sub>1</sub>-C<sub>6</sub>alkyl or C<sub>7</sub>-C<sub>12</sub>aralkyl, wherein the C<sub>7</sub>-C<sub>12</sub>aralkyl group is optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

46. (Original) The compound of Claim 45, namely, 1-(6-[4-(1-Benzylpiperidine-4-carbonyl)ciperazin-1-yll-pyridin-3-yll-3-pentylurea.

- 47. (Original) The compound of Claim 40 wherein R³ is pyridinyl optionally substituted by one or more substituents selected from the group consisting of halo or C₁-C₀alkyl.
- 48. (Original) The compound of Claim 47 selected from the group consisting of the following:

1-Pentyl-3-{6-[4-(pyridine-2-carbonyl)piperazin-1-yl]-pyridin-3-yl}urea; and 1-Pentyl-3-{6-[4-(pyridine-4-carbonyl)piperazin-1-yl]-pyridin-3-yl}urea.

- 49. (Original) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 37.
- (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 37.
  - 51. (Currently Amended) The compound of formula (V):

$$R^{2} - W_{a} - V_{a} - V_{a$$

wherein:

x and y are each independently 1, 2 or 3;

 $W_a$  is -O-, -N(R<sup>1</sup>)- or -S(O)<sub>t</sub>- (where t is 0, 1 or 2);

 $V_a \text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -C(O)O-, -C(S)O-, -S(O)-(where t is 1 or 2) or -S(O)_tN(R^1)- (where t is 1 or 2);}$ 

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_{1-C_{12}alkyl}$ ,  $C_{2-C_{12}hydroxyalkyl}$ ,  $C_{4-C_{12}cycloalkylalkyl}$  and  $C_{7-C_{19}aralkyl}$ ;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12} \text{alkyl}, C_2\text{-}C_{12} \text{alkenyl}, \\ C_2\text{-}C_{12} \text{hydroxyalkyl}, C_2\text{-}C_{12} \text{hydroxyalkenyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, \\ C_4\text{-}C_{12} \text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19} \text{aralkyl}, C_3\text{-}C_{12} \text{ heterocyclyl}, C_3\text{-}C_{12} \text{heterocyclylalkyl}, \\ C_1\text{-}C_{12} \text{heteroaryl} \text{ and } C_3\text{-}C_{12} \text{heteroarylalkyl}; \\ \end{cases}$ 

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;

 $R^3 \ \text{is selected from the group consisting of } C_1\text{-}C_{12} \text{alkyl}, \ C_2\text{-}C_{12} \text{alkenyl}, \\ C_2\text{-}C_{12} \text{hydroxyalkyl}, \ C_2\text{-}C_{12} \text{hydroxyalkenyl}, \ C_2\text{-}C_{12} \text{alkoxyalkyl}, \ C_3\text{-}C_{12} \text{cycloalkyl}, \\ C_4\text{-}C_{12} \text{cycloalkylalkyl}, \ \text{aryl}, \ C_7\text{-}C_{19} \text{aralkyl}, \ C_3\text{-}C_{12} \text{heterocyclyl}, \ C_3\text{-}C_{12} \text{heterocyclylalkyl}, \\ C_1\text{-}C_{12} \text{heteroaryl} \ \text{and} \ C_3\text{-}C_{12} \text{heteroarylalkyl}, \\ C_1\text{-}C_{12} \text{heteroarylalkyl}, \\ C_2\text{-}C_{12} \text{heteroarylalky$ 

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{19})_{z}$ ;

 $R^7$ ,  $R^{7s}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10s}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or R<sup>7</sup>-and R<sup>7a</sup>-together, or R<sup>8</sup>and R<sup>8a</sup>-together, or R<sup>9</sup>and R<sup>9a</sup>-together, or R<sup>9a</sup>-and R<sup>1a</sup>-together, or R<sup>9a</sup>-and R<sup>1a</sup>-together are an exe-group, provided that when V<sub>a</sub>-is – C(O) – R<sup>7</sup>and R<sup>7a</sup>-together or R<sup>8</sup> and R<sup>8a</sup>-together do not form an exe-group, while the remaining R<sup>7</sup> – R<sup>7a</sup> – R<sup>8</sup> , R<sup>8</sup> , R<sup>8a</sup> – R<sup>9</sup> , R<sup>8a</sup> – R<sup>9</sup> , R<sup>8a</sup> – R<sup>9</sup> – R<sup>9a</sup> – R<sup>9</sup>

er one of  $R^{10}$ ,  $R^{7}$ , and  $R^{7a}$  together with one of  $R^{8}$ ,  $R^{8a}$ ,  $R^{9}$  and  $R^{6a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{9a}$ ,  $R^{7a}$ ,  $R^{8}$ ,  $R^{8a}$ ,  $R^{9}$ , and  $R^{8a}$  are each independently solected from hydrogen or  $C_3$ - $C_3$ alkyl; and

each R13 is independently selected from hydrogen or C₁-C₀alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

(Currently Amended) The compound of Claim 51 wherein:
 x and y are each independently 1, 2 or 3;

W<sub>a</sub> is -O-, -N(R<sup>1</sup>)- or -S(O)<sub>t</sub>- (where t is 0, 1 or 2);

 $V_a \text{ is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(S)N(R^1)-, -C(O)O-, -S(O)-(where t \text{ is 1 or 2})} \\ \text{or -S(O),N(R^1)- (where t \text{ is 1 or 2});} \\$ 

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12} \text{alkyl}, C_2\text{-}C_{12} \text{alkenyl}, C_2\text{-}C_{12} \text{nydroxyalkenyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, C_3\text{-}C_{12} \text{cycloalkylalkyl}, aryl, C_7\text{-}C_{19} \text{aralkyl}, C_3\text{-}C_{12} \text{ heterocyclyl}, C_3\text{-}C_{12} \text{heterocyclylalkyl}, C_1\text{-}C_4\text{-}heteroaryl and } C_3\text{-}C_1\text{-}heteroarylalkyl};$ 

 $R^3 \ is \ selected from the group consisting of $C_1\text{-}C_{12}$alkyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$bydroxyalkyl, $C_2\text{-}C_{12}$bydroxyalkenyl, $C_2\text{-}C_{12}$alkenyl, $C_3\text{-}C_{12}$cycloalkyl, $C_3\text{-}C_{12}$cycloalkyl, aryl, $C_7\text{-}C_9$aralkyl, $C_3\text{-}C_{12}$heterocyclyl, $C_3\text{-}C_{12}$heterocyclylalkyl, $C_1\text{-}C_9$heteroaryl and $C_3\text{-}C_{12}$heteroarylalkyl;}$ 

R<sup>4</sup>, R<sup>5</sup> and R<sup>5</sup> are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>13</sup>)<sub>2</sub>;

 $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},\,\text{and}\,R^{10a}\,\text{are each independently selected from hydrogen or C_1-C_3alkyl; and}$ 

each R<sup>13</sup> is independently selected from hydrogen or C₁-C₀alkyl.

53. (Original) The compound of Claim 52 wherein:

x and y are each 1;

W<sub>a</sub> is -O-:

 $V_a$  is -C(O)- or -C(S)-;

 $R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, \\ C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_3-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, \\ C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12}heterocyclylalkyl, \\ C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl; \\ C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl; \\ \\$ 

 $R^3 \ \text{is selected from the group consisting of $C_3$-$C_{12}$alkyl, $C_3$-$C_{12}$alkenyl, $C_3$-$C_{12}$alkenyl, $C_3$-$C_{12}$bydroxyalkyl, $C_3$-$C_{12}$alkoxy, $C_3$-$C_{12}$alkoxyalkyl, $C_3$-$C_{12}$vcloalkyl, $C_3$-$C_{12}$vcloalkylalkyl, aryl, $C_7$-$C_{19}$aralkyl, $C_3$-$C_{12}$heterocyclyl, $C_3$-$C_{12}$heterocyclylalkyl, $C_1$-$C_{12}$heteroaryl and $C_3$-$C_{12}$heteroarylalkyl;$ 

 $R^4$ ,  $R^5$  and  $R^8$  are each hydrogen; and  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^8$ ,  $R^8$ ,  $R^{8}$ ,  $R^{10}$ , and  $R^{10a}$  are each hydrogen.

54. (Original) The compound of Claim 53 wherein:

Va is -C(O)-;

 $R^2 is selected from the group consisting of $C_1\text{-}C_{12}alkyl, $C_3\text{-}C_{12}cycloalkyl,$$$ $C_4\text{-}C_{12}cycloalkyl, aryl, $C_7\text{-}C_{19}aralkyl, $C_3\text{-}C_{12}$ heterocyclyl, $C_3\text{-}C_{12}$ heterocyclylalkyl, $C_7\text{-}C_7$ heteroaryl and $C_3\text{-}C_{12}$ heteroarylalkyl; are $C_3\text{-}C_{12}$ heteroarylalkyl; and $C_3\text{-}C_{12}$ heteroarylalkyl; are $C_3\text{-}C_{12}$ heteroary$ 

 $R^3 \text{ is selected from the group consisting of $C_3\text{-}C_{12}$ cycloalkyl, $C_4\text{-}C_{12}$ cycloalkyl, aryl, $C_7\text{-}C_{19}$ aralkyl, $C_3\text{-}C_{12}$ heterocyclylalkyl, $C_4\text{-}C_{12}$ heteroaryl and $C_3\text{-}C_{12}$ heteroarylalkyl.}$ 

55. (Original) The compound of Claim 52 wherein:

x and v are each 1;

W<sub>a</sub> is -N(R<sup>1</sup>)-;

V<sub>2</sub> is -C(O)- or -C(S)-;

R1 is hydrogen or C1-C6alkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12} \text{alkeyl}, C_2\text{-}C_{12} \text{alkenyl}, C_2\text{-}C_{12} \text{hydroxyalkyl}, C_3\text{-}C_{12} \text{hydroxyalkenyl}, C_3\text{-}C_{12} \text{alkoxyalkyl}, C_3\text{-}C_{12} \text{cycloalkyl}, C_4\text{-}C_{12} \text{cycloalkyl}, \text{aryl}, C_7\text{-}C_{19} \text{aralkyl}, C_3\text{-}C_{12} \text{ heterocyclyl}, C_3\text{-}C_{12} \text{heterocyclylalkyl}, C_1\text{-}C_{12} \text{heteroaryl}, \text{ardl}, C_1\text{-}C_1\text{-}h \text{heteroaryl}, \text{ardl}, C_2\text{-}C_1\text{-}h \text{eteroaryl}, \text{ardl}, C_1\text{-}C_1\text{-}h \text{eteroaryl}, C_1\text{-}C$ 

 $R^3$  is selected from the group consisting of  $C_3\text{-}C_{12}$ alkyl,  $C_9\text{-}C_{12}$ alkenyl,  $C_3\text{-}C_{12}\text{hydroxyalkyl}, C_3\text{-}C_{12}\text{hydroxyalkenyl}, C_3\text{-}C_{12}\text{alkoxy}, C_9\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_{12}\text{-}C_{12$ 

 $R^4,\,R^5$  and  $R^6$  are each hydrogen; and  $R^7,\,R^{7a},\,R^8,\,R^{8a},\,R^9,\,R^{9a},\,R^{10},\,\text{and}\,\,R^{10a}\,\text{are each hydrogen}.$ 

56. (Original) The compound of Claim 55 wherein:

 $V_a$  is -C(O)-;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_{12}\text{alkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12} \text{ heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_1\text{-}C_{12}\text{heteroaryl} \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_1\text{-}C_{12}\text{heteroaryl} \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_1\text{-}C_{12}\text{heteroaryl} \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_1\text{-}C_{12}\text{heteroaryl} \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_2\text{-}C_{12}\text{heteroaryl} \text{ and } C_3\text{-}C_{12}\text{heteroarylalkyl}, \\ C_3\text{-}C$ 

 $R^3 is selected from the group consisting of C_3-C_{12} cycloalkyl, C_4-C_{12} cycloalkylalkyl, aryl, C_7-C_{19} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_7-C_{12} heteroaryl and constant of the c$ 

## C3-C12heteroarylalkyl.

57. (Original) The compound of Claim 52 wherein:

x and y are each 1;

W<sub>a</sub> is -S(O)<sub>r</sub>- (where t is 0, 1 or 2);

V₂ is -C(O)- or -C(S)-;

 $R^2 is \ selected from the group consisting of C_1-C_{12} alkyl, \ C_2-C_{12} alkenyl, \\ C_2-C_{12} hydroxyalkyl, \ C_2-C_{12} hydroxyalkyl, C_3-C_{12} cycloalkyl, \\ C_3-C_{12} hydroxyalkyl, C_3-C_{12} cycloalkyl, \\ C_3-C_{12} hydroxyalkyl, C_3-C_{12} cycloalkyl, \\ C_3-C_{12} hydroxyalkyl, \\ C_3-C_{12} hydroxyalkyl$ 

C<sub>2</sub>-C<sub>12</sub>nydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>nydroxyalkellyl, C<sub>3</sub>-C<sub>12</sub>nkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>beterocyclylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>3</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>12</sub>alkenyl,

$$\begin{split} &C_3\text{--}C_{12}\text{hydroxyalkyl},\ C_3\text{--}C_{12}\text{hydroxyalkenyl},\ C_3\text{--}C_{12}\text{alkoxy},\ C_3\text{--}C_{12}\text{alkoxyalkyl},\ C_3\text{--}C_{12}\text{cycloalkyl},\\ &C_4\text{--}C_{12}\text{cycloalkylalkyl},\ \text{aryl},\ C_7\text{--}C_{19}\text{aralkyl},\ C_3\text{--}C_{12}\text{heterocyclyl},\ C_3\text{--}C_{12}\text{heterocyclylalkyl},\ C_1\text{--}C_{12}\text{heteroaryl},\\ &\text{heteroaryl}\ \text{and}\ C_3\text{--}C_{12}\text{heteroarylalkyl}; \end{split}$$

 $R^4$ ,  $R^5$  and  $R^6$  are each hydrogen; and  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^8$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each hydrogen.

(Original) The compound of Claim 57 wherein:

 $V_a$  is -C(O)-;

 $R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkyl, aryl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_4$ - $C_4$ -heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl; and

 $R^3 is selected from the group consisting of C_3-C_{12} cycloalkyl, C_4-C_{12} cycloalkylalkyl,\\ aryl, C_7-C_{19} aralkyl, C_3-C_{12} heterocyclyl, C_3-C_{12} heterocyclylalkyl, C_1-C_{12} heteroaryl and C_3-C_{12} heteroarylalkyl.$ 

- 59. (Original) A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 51.
- (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 51.

## 61. (Currently Amended) A compound of formula (la):

wherein:

x and v are each independently 1, 2 or 3;

W is -N(R1)S(O)r (where t is 1 or 2);

 $\label{eq:Vis-C(O)-,-C(S)-,-C(O)N(R^1)-,-C(S)N(R^1)-,-C(O)O-,-C(S)O-,-S(O)-(where t is 1 or 2), -S(O),N(R^1)- (where t is 1 or 2) or -C(R^11)H;}$ 

each R1 is independently selected from the group consisting of hydrogen,

C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R2 is selected from the group consisting of C1-C12alkyl, C2-C12alkenyl,

$$\begin{split} &C_{2^{**}}C_{12}\text{hydroxyalkyl},\ C_{2^{**}}C_{12}\text{hydroxyalkenyl},\ C_{2^{**}}C_{12}\text{alkoxyalkyl},\ C_{3^{**}}C_{12}\text{cycloalkyl},\\ &C_{4^{**}}C_{12}\text{cycloalkylalkyl},\ \text{aryi},\ C_{7^{**}}C_{19}\text{aralkyl},\ C_{3^{**}}C_{12}\text{heterocyclyl},\ C_{3^{**}}C_{12}\text{heterocyclylalkyl},\\ &C_{1^{**}}C_{11}\text{heteroaryl},\ \text{and}\ C_{3^{**}}C_{12}\text{heteroarylalkyl}; \end{split}$$

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^3 \ \text{is selected from the group consisting of $C_1\text{-}C_{12}$alkyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_2\text{-}C_{12}$alkenyl, $C_3\text{-}C_{12}$alkenyl, $C_3\text$ 

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

 $R^4$ ,  $R^5$  and  $R^6$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{16})_2$ ;

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or Cr-C-alkyl:

or  $R^7$ -and  $R^{7o}$ -together, or  $R^8$ and  $R^{8o}$ -together, or  $R^9$  and  $R^{9o}$ -together, or  $R^{1o}$ -and  $R^{1o}$ -together are an oxo-group, provided that when V is -C(O),  $R^7$  and  $R^{7o}$ -together or  $R^9$ -and  $R^{8o}$ -together do not form an oxo-group, while the remaining  $R^7$ ,  $R^{7o}$ ,  $R^8$ ,  $R^{8o}$ ,  $R^9$ ,  $R^{8o}$ ,  $R^{1o}$ , and  $R^{10o}$ -are each independently selected from hydrogen or  $C_1C_2$  alkyl;

or one of  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ , and  $R^{7a}$  together with one of  $R^8$ ,  $R^{8a}$ ,  $R^9$  and  $R^{9a}$  form an alkylene bridge, while the remaining  $R^{10}$ ,  $R^{10a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^8$ , and  $R^{8a}$  are each independently selected from hydrogen or  $C_3$ .  $C_3$ alkyl;

R11 is hydrogen or C1-C3alkyl; and

each R13 is independently selected from hydrogen or C1-C6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

(Currently Amended) The compound of Claim 61 wherein:
 x and v are each independently 1, 2 or 3;

V is -C(O)- or -C(S)-:

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and

C7-C19aralkyl;

 $R^2 \text{ is selected from the group consisting of } C_1\text{-}C_12\text{alkyl}, C_2\text{-}C_12\text{alkenyl}, \\ C_2\text{-}C_{12}\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_2\text{-}C_{12}\text{alkoxyalkyl}, C_3\text{-}C_{12}\text{cycloalkyl}, \\ C_4\text{-}C_{12}\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_{19}\text{aralkyl}, C_3\text{-}C_{12}\text{heterocyclyl}, C_3\text{-}C_{12}\text{heterocyclylalkyl}, \\ C_4\text{-}C_4\text{-heteroaryl}, \text{and } C_3\text{-}C_{12}\text{heteroarylalkyl}; \\ C_4\text{-}C_4\text{-heteroaryl}, \text{and } C_3\text{-}C_{12}\text{heteroarylalkyl}; \\ R_4\text{-}C_4\text{-heteroaryl}, \text{and } C_3\text{-}C_{12}\text{heteroarylalkyl}; \\ R_4\text{-}C_4\text{-heteroaryl}, \text{and } C_3\text{-}C_{12}\text{-heteroarylalkyl}; \\ R_4\text{-}C_4\text{-}C_4\text{-heteroarylalkyl}; \\ R_4\text{-}C_4\text{-}C_4\text{-heteroarylalkyl}; \\ R_4\text{-}C_4\text{-}C_4\text{-}C_4\text{-}C_4\text{-heteroarylalkyl}; \\ R_4\text{-}C$ 

 $R^3 \text{ is selected from the group consisting of } C_1\text{-}C_12\text{alkyl}, C_2\text{-}C_12\text{alkenyl}, \\ C_2\text{-}C_12\text{hydroxyalkyl}, C_2\text{-}C_{12}\text{hydroxyalkenyl}, C_1\text{-}C_12\text{alkoxy}, C_2\text{-}C_12\text{alkoxyalkyl}, C_3\text{-}C_12\text{cycloalkyl}, \\ C_4\text{-}C_12\text{cycloalkylalkyl}, \text{aryl}, C_7\text{-}C_19\text{aralkyl}, C_3\text{-}C_12\text{heterocyclyl}, C_3\text{-}C_12\text{heterocyclylalkyl}, \\ C_4\text{-}C_12\text{-}C_12\text{heteroaryl} \text{ and } C_3\text{-}C_12\text{heteroarylalkyl}; \\ C_3\text{-}C_12\text{-}C_12\text{heteroaryl} \text{ and } C_3\text{-}C_12\text{heteroarylalkyl}; \\ C_3\text{-}C_12\text{-}$ 

 $R^4$ ,  $R^5$  and  $R^8$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{18})_2$ ;

 $R^7, R^{7a}, R^8, R^{8a}, R^9, R^{9a}, R^{10}, \text{ and } R^{10a} \text{ are each independently selected from hydrogen or } C_1\text{-}C_3\text{alkyl}; \text{ and }$ 

each R<sup>13</sup> is independently selected from hydrogen or C₁-C₅alkyl.

63. (Original) The compound of Claim 62 wherein: x and v are each 1;

V is -C(O)-:

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

 $R^2 \text{ is selected from the group consisting of } C_{1^*C_{12}} \text{alkyl}, C_{2^*C_{12}} \text{alkenyl}, \\ C_{3^*C_{12}} \text{cycloalkyl}, C_{4^*C_{12}} \text{cycloalkylalkyl}, C_{7^*C_{15}} \text{aralkyl}, C_{3^*C_{12}} \text{heterocyclylalkyl} \text{ and } C_{3^*C_{12}} \text{heteroarylalkyl}; \\$ 

 $R^3$  is aryl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1\text{-}C_6$ alkyl,  $C_1\text{-}C_6$ trihaloalkyl,  $C_1\text{-}C_6$ trihaloalkyl,  $C_1\text{-}C_6$ alkylsulfonyl,  $\text{-N}(R^{12})_2$ ,  $\text{-OC}(O)R^{12}$ ,  $\text{-C}(O)OR^{12}$ ,  $\text{-S}(O)_2N(R^{12})_2$ , cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl;

 $R^4$ ,  $R^5$  and  $R^5$  are each independently selected from hydrogen, bromo, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^{13})_2$ ;

 $R^7$ ,  $R^{7a}$ ,  $R^a$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$ , and  $R^{10a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl; and

each  $R^{13}$  is independently selected from hydrogen or  $C_1\text{-}C_6$ alkyl.

64. (Original) The compound of Claim 63 wherein:

x and y are each 1;

V is -C(O)-:

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

R2 is C1-C12alkyl or C2-C12alkenyl;

 $R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_0$ ellkyl,  $C_1$ - $C_0$ trihaloalkyl,  $C_1$ - $C_0$ trihaloalkyl,  $C_1$ - $C_0$ ellkylsulfonyl,  $-N(R^{12})_2$ ,  $-OC(O)R^{12}$ ,  $-C(O)OR^{12}$  and  $-S(O)_2N(R^{12})_2$ ;

 $\mbox{R}^4, \mbox{R}^5$  and  $\mbox{R}^6$  are each independently selected from hydrogen, bromo, fluoro or chloro; and

R7, R7a, R8, R8a, R9, R9a, R10 and R10a are each hydrogen.

65. (Original) The compoundof Claim 63 wherein:

x and v are each 1;

V is -C(O)-;

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

R2 is C3-C12cycloalkyl or C4-C12cycloalkylalkyl;

R3 is phenyl optionally substituted by one or more substituents selected from the

Docket No.: 17243/003001

group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup> and -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>;

 $R^4, R^5$  and  $R^8$  are each independently selected from hydrogen, bromo, fluoro or chloro: and

 $R^7$ ,  $R^{7a}$ ,  $R^8$ ,  $R^{8a}$ ,  $R^9$ ,  $R^{9a}$ ,  $R^{10}$  and  $R^{10a}$  are each hydrogen.

66. (Original) The compound of Claim 65 wherein:

R2 is C4-C12cycloalkylalkyl;

 $R^3$  is phenyl optionally substituted by one or more substituents selected from halo,  $C_1$ - $C_6$ elikyl,  $C_1$ - $C_6$ trihaloalkyl and  $C_1$ - $C_6$ trihaloalkoxy;

R4 and R6 are both hydrogen; and

R<sup>5</sup> is hydrogen or bromo.

- 67. (Original) The compound of Claim 66 selected from the group consisting of the following:
- 5-Bromo-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridine-3-sulfonic acid (2-cyclopropylethyl)amide; and
- 6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]pyridine-3-sulfonic acid (2-cyclopropylethyl)amide.
  - 68. (Original) The compound of Claim 63 wherein:

x and y are each 1;

V is -C(O)-:

R1 is hydrogen, C1-C12alkyl or C4-C12cycloalkylalkyl;

R<sup>2</sup> is C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl or C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

 $R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_0$ elikyl,  $C_1$ - $C_0$ trihaloalkyl,  $C_1$ - $C_0$ trihaloalkyxy,  $C_1$ - $C_0$ trihaloalkyxy,  $C_1$ - $C_0$ trihaloalkyl,  $C_1$ - $C_0$ trihaloalkyxy,  $C_1$ - $C_0$ trihaloalky

 $R^4, R^5 \, \text{and} \, R^6 \, \text{are each independently selected from hydrogen, bromo, fluoro or chloro: and$ 

R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, R<sup>8a</sup>, R<sup>9</sup>, R<sup>9a</sup>, R<sup>10</sup>, and R<sup>10a</sup> are each hydrogen.

69. (Original) A method of treating a disease or condition mediated by stearoyl-CoA

desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 61.

70. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 61.

28